abdominal pain, nausea and vomiting were included for this study. Those with fever due to urinary tract infection/malaria/enteric fever; culture-positive bacterial pneumonia; patients with other bloodstream infections; bleeding disorders and fever for more than four weeks duration (pulmonary tuberculosis), were excluded.
A total of 76 patients were selected initially, but only 41 patients provided both acute and convalescent blood samples. Acute samples were collected when the patients had symptoms of 1-15 days duration. Convalescent samples were collected two to three weeks later. The serum was separated, aliquoted and kept frozen at −20ºC till the performance of IFA and qPCR. The interval between the collection of blood samples and testing for IFA and qPCR varied from one to five months. IFA was performed in batches and for QF qPCR, the samples were sent to Defence Research and Development Establishment (DRDE), Gwalior, where batch testing was carried out. IFA was carried out on acute as well as convalescent serum samples to detect IgM and IgG antibodies for both phase I and II. C. burnetii IFA (Fuller Laboratories, California, USA), QM-120 and QG-120 kits were employed, strictly adhering to the instructions of the manufacturers. Slides were scored as negative, 1+, 2+, 3+ and 4+. As per the kit, the significant titre in acute QF for phase II IgM was 1: 16 were confirmed by serology alone as acute QF, since they were positive for both phase II IgM and IgG with significant titres. The fifth patient (Sl. No. 5) showed titre of 1:64 for phase I IgG (significant) but not for phase II IgG (titre was only 1:64, whereas the significant titre was ≥1:128). The sixth patient was positive for only phase II IgM (1:32) hence considered seronegative, but Table II details the clinical and laboratory parameters of C. burnetii antibody positive and negative patients. Most of these patients had common clinical features such as myalgia, chills and rigor, abdominal pain, nausea, vomiting and hepatomegaly. No significant differences were observed between the two categories except for splenomegaly (P<0.05). Five IFA positive (including two qPCR positive) and 13 IFA negative patients had a history of domestic animal contact such as cattle, sheep, goat, dog or their residence situated near the abattoir (Table I) .
QF PCR is positive in the early stage of acute illness and tends to become negative when antibodies start appearing. The chronological order of appearance of antibodies in acute QF is as follows: IgM phase II → IgG phase II → IgM phase I → IgG phase I 15 . Phase II IgM antibodies are present in acute infection, whereas phase I antibodies are associated with chronic infections 1, 5, 8, 12, 13 . Detection of phase II IgG in both acute and convalescent samples and demonstration of seroconversion/four-fold increase in titre confirms a diagnosis of acute QF 8 . The presence of solitary phase II IgM in acute samples has little significance 11 .
Laboratory definition and interpretation of acute QF 9 based on gold standard IFA is as follows: (i) IgM phase II + IgG phase II antibodies → acute QF; (ii) IgG phase II with or without IgG phase I → resolved past QF; and (iii) other combination viz., IgM/IgG phase II and/or IgM/IgG phase I → inconclusive, PCR to be performed.
Of the 41 patients who provided paired samples, nine (22.0%) were diagnosed with acute QF and 10 (24.4%) were regarded as past QF (Table I) . IgM phase II antibodies to C. burnetii remains for several months, unlike other infections, hence the relevance of IgG phase II over IgM phase II has been stressed 7 .
In conclusion, the present study showed presence of QF in and around Puducherry. Notwithstanding the sophistication, exorbitant cost and the need for importing the kits, acute QF diagnosis mandates the performance of IFA for screening and real-time PCR for confirmation. Whenever there is a strong clinical suspicion of acute QF, search for C. burnetii DNA in the clinical samples by PCR is mandatory, even if the patient's acute samples are negative for IgM and IgG antibodies in IFA. All attempts should be made Low platelet count (≤150,000 millions/ml) 
